Policy Options for Formulary Development in Middle-income Countries: Mexico Case Study
T. Towse and
Consulting Reports from Office of Health Economics
PhRMA commissioned OHE Consulting to explore options and recommend methods that could help middle-income countries efficiently and effectively identify medicines for formulary inclusion. In a previous publication we presented a framework for developing medicines formularies which combines macro-level decision making factors (focusing on the health system organisation and its priority setting), and micro-level factors (looking at intervention-specific effects) to determine the overall value of medicines (click [here]( https://www.ohe.org/publications/policy-options-formulary-development-middle-income-countries#overlay-context=publications/policy-options-formulary-development-middle-income-countries-mexico-case-study) to access). In this report we apply this framework to analyse the Mexican decision making process for the inclusion of a new health treatment in the positive list. We propose a series of recommendations that could improve the efficiency of the Mexican decision making process.
Keywords: Economics; of; Health; Technology; Assessment (search for similar items in EconPapers)
JEL-codes: I1 (search for similar items in EconPapers)
References: View references in EconPapers View complete reference list from CitEc
Citations: Track citations by RSS feed
Downloads: (external link)
https://www.ohe.org/system/files/private/publicati ... 017%20final%20v2.pdf (application/pdf)
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
Persistent link: https://EconPapers.repec.org/RePEc:ohe:conrep:001781
Access Statistics for this paper
More papers in Consulting Reports from Office of Health Economics Contact information at EDIRC.
Bibliographic data for series maintained by Publications Manager ().